Award recognizes Transplant Genomics’ innovative strides towards improving the health and care of kidney transplant recipients.

FRAMINGHAM, MA — Transplant Genomics (“TGI”), the transplant rejection diagnostics company committed to improving organ transplant outcomes worldwide, is honored to accept the Medical Innovation Award from the National Kidney Foundation, to be presented at the annual Kidney Gift of Life Honors celebrating World Kidney Day on March 11, 2021.

Transplant Genomics’ flagship product is TruGraf, the only non-invasive blood gene expression test approved by CMS, which offers the earliest possible detection of “silent” subclinical acute rejection in kidney transplant recipients with stable kidney function, before organ injury and chronic acute rejection begins.

Nicholas Grund, President of Transplant Genomics, will accept the award on behalf of the company during the gala event, being held virtually this year.

Erin Tuladzieck, Executive Director, National Kidney Foundation Serving the Alleghenies, said:

“The National Kidney Foundation is pleased to honor Transplant Genomics as this year’s Medical Innovation Awardee at the upcoming Kidney Gift of Life Honors event on World Kidney Day, March 11. This award recognizes an individual or an organization for the innovative strides they have taken in their field to improve the health and care of those in our community affected by kidney disease or organ transplantation. Transplant Genomics is so well respected in the community and this award is so well deserved. We are grateful to have Transplant Genomics’ amazing support of our lifesaving mission.”

Mr. Grund remarked:

“Transplant Genomics is honored to accept this Medical Innovation Award on the behalf of our scientists, clinicians, laboratory technicians, and business professionals who work together to bring the TruGraf test to kidney patients. Early on we at TGI recognized that the number of transplant patients experiencing acute rejection and losing their kidney transplants was too high. In addition, the tools available to physicians to help determine kidney transplant health were limited. If we were able to help physicians catch the signs of subclinical rejection earlier, the physician could act and hopefully reduce the number of kidney transplant rejections. That led us to develop TruGraf, the first and only blood-based test that uses gene expression profiling to rule out “silent” subclinical acute rejection in patients with stable renal function.”

“With TruGraf, clinicians can focus on the patients who need the most attention, while transplant kidney patients gain peace of mind knowing that their kidney is doing okay,” he continued.

“I want to thank the National Kidney Foundation for this tremendous honor. But rest assured we are continuing to innovate in our pursuit of improving organ transplant outcomes worldwide.”

For more information:

Branden Morris
Transplant Genomics, Inc.
p) 510-745-4707


About Transplant Genomics, Inc.

Transplant Genomics, Inc. (“TGI”) is a personalized diagnostics company committed to improving organ transplant outcomes worldwide through innovative tests that detect early signs of graft injury, differentiate among actionable causes, and enable the optimization of therapy. Working alongside the transplant community and within the Eurofins family, TGI is commercializing a suite of tests enabling diagnoses and prediction of transplant recipient immune status. Our flagship product is TruGraf, the only non-invasive blood test approved by CMS that offers the earliest possible detection of “silent” subclinical acute rejection in kidney transplant recipients with stable graft function. Test services are offered through TGI’s CLIA laboratory in Fremont, CA. TGI was acquired by Eurofins Scientific in 2019.

Learn more about Transplant Genomics at

About Eurofins Scientific

Eurofins Scientific, through its subsidiaries (hereinafter “Eurofins” or “the Group”), believes it is the global leader in food, environmental, pharmaceutical and cosmetics products testing and in agroscience CRO services. It is also one of the global independent market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, CDMO, advanced material sciences and in the support of clinical studies. In addition, Eurofins is one of the leading global emerging players in esoteric and molecular clinical diagnostic testing. With over 50,000 staff across a network of more than 900 independent companies in over 50 countries generally specialised by end client markets and operating more than 800 laboratories, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of a wide range of products, as well as providing innovative clinical diagnostic testing services. The Group’s objective is to provide its customers with high-quality and innovative services, accurate results on time and, when requested, expert advice by its highly-qualified staff.

Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and a very large range of testing methods.

As one of the most innovative and quality-oriented international groups in its industry, Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the increasing demands of regulatory authorities and healthcare practitioners around the world.

Shares in Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).

Learn more about Eurofins at

About the National Kidney Foundation

Fueled by passion and urgency, NKF is a lifeline for all people affected by kidney disease. As pioneers of scientific research and innovation, NKF focuses on the whole patient through the lens of kidney health. Relentless in our work, we enhance lives through action, education, and accelerating change.

Learn more about the National Kidney Foundation at